|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2005
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:ATCCode
|
L04AA24
|
|
gptkbp:CASNumber
|
332348-12-6
|
|
gptkbp:contraindication
|
hypersensitivity to abatacept
|
|
gptkbp:drugClass
|
gptkb:immunosuppressant
biologic disease-modifying antirheumatic drug
|
|
gptkbp:form
|
pre-filled syringe
powder for solution for infusion
auto-injector
|
|
gptkbp:genericName
|
gptkb:abatacept
|
|
gptkbp:halfLife
|
13-16 days
|
|
gptkbp:indication
|
gptkb:juvenile_idiopathic_arthritis
gptkb:psoriatic_arthritis
rheumatoid arthritis
|
|
gptkbp:KEGGID
|
D06402
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:mechanismOfAction
|
selective T-cell co-stimulation modulator
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionStatus
|
Rx-only
|
|
gptkbp:product
|
gptkb:protein
|
|
gptkbp:PubChem_CID
|
CHEMBL1201832
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
nausea
headache
hypertension
infections
infusion reactions
|
|
gptkbp:storage
|
2°C to 8°C
|
|
gptkbp:target
|
gptkb:CTLA-4
gptkb:CD80
gptkb:CD86
|
|
gptkbp:UNII
|
3KX376GY7L
|
|
gptkbp:bfsParent
|
gptkb:Bristol_Myers_Squibb
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Orencia
|